Update on Global Regulators Meeting on COVID-19
The International Coalition of Medicines Regulatory Authorities met again on June 12 to discuss policy approaches to the COVID-19 pandemic.
On June 12, 2020, the International Coalition of Medicines Regulatory Authorities (ICMRA) met for the fifth time in a virtual meeting moderated by FDA’s Janet Woodcock, director of the Center for Drug Evaluation and Research, to discuss policy approaches to the COVID-19 pandemic. The group reviewed the principals for COVID-19 clinical trials and prioritization of compounds. Concerns about the discontinuation of clinical trials and the number of underpowered studies were expressed by the group. The use of COVID-19 clinical trial master protocols to accelerate treatment development was also discussed. The group is working to compare master protocols from different countries to identify possible overlaps.
An update on clinical trials, potential therapies, and vaccines was given by the ICMRA Working Group on COVID-19. “Topics under discussion include ethical questions around human challenge trials and post-approval requirements for COVID-19 vaccines. ICMRA members agreed to analyze the regulatory flexibilities and extraordinary measures applied in different areas during the pandemic in order to identify practices that should be maintained or stopped after the public health emergency. The ICMRA COVID-19 Working Group will keep updating all ICMRA members on the progress of these initiatives,” the European Medicines Agency stated in a press release.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
